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Abstract 
 
PURPOSE: Describe an unusual case of bilateral pigment dispersion syndrome (PDS) following 
years of uninterrupted treatment with Atropine 1% for bilateral congenital cataracts, speculate on 
potential mechanisms leading to this condition. 
 
DESIGN: Case report. 
 
CASE: A 45-year-old Caucasian patient on long term treatment with Atropine 1% ointment since his 
infancy for bilateral congenital cataracts developed pigmentary dispersion syndrome (PDS) with 
secondary ocular hypertension (OHT). 
 
RESULTS: The patient showed all the hallmarks of PDS with secondary OHT. An anterior segment 
Swept- Source OCT was obtained to review the iris profile. The patient showed good pressure 
response to topical prostaglandin therapy. 
 
CONCLUSIONS: This is the second case report of PDS in a patient with chronic use of topical 
Atropine. The proposed mechanisms for pigment dispersion are discussed and the possibility raised 
of dispersion being a potential side effect of the drug. 
 
KEYWORDS: Pigmentary Dispersion Syndrome, PDS, Atropine, Ocular Hypertension, Congenital 
Cataracts. 
  
CASE REPORT 
A 45-year-old Caucasian gentleman was referred by his optician to the Glaucoma Clinic for raised 
intraocular pressure and disc cup asymmetry. He had congenital cataract treated uninterruptedly 
since early childhood with Atropine 1% ointment once every 5 days and esotropia with left 
amblyopia. He also reported a family history of congenital cataract. On examination his best 
corrected visual acuities were 6/12 in the right and 2/60 in the left, amblyopic eye. Both eyes 
showed a significant degree of compound myopic astigmatism (right eye: sphere -4.00/ -5.00x110°; 
left eye: sphere -3.00/ -3.00x60°). Both pupils were pharmacologically mid-dilated with blue irides 
and lamellar cataracts in both eyes. He showed several hallmark signs of pigment dispersion 
syndrome with marked Krukenberg spindles and360 degree spoke-like transillumination defects of 
the iris. On gonioscopy the angles were wide open with heavy 360 degree continuous pigmentation 
on the trabecular meshwork; no peripheral anterior synechiae (PAS) or central posterior synechiae 
(CPS) were observed and the iris profile was noted to be concave. His corneal thickness was 580 
microns in the right and 598 microns in the left eye and the intraocular pressures (IOP) were 25 
mmHg in the right and 28 mmHg in the left eye. Fundus examination demonstrated large optic discs, 
measuring 2.0 mm in vertical diameter, and cup-to-disc asymmetry, the right eye having a 0.6 cup 
and left eye a 0.4 cup with no visible nerve fibre layer defect. Visual field analysis was bilaterally full. 
Anterior segment photographs and Swept-Source anterior segment OCT (SS AS-OCT) scans with 
three-dimensional reconstruction are shown in Fig. 1. His diagnosis was bilateral congenital cataracts 
and pigment dispersion syndrome (PDS) with secondary ocular hypertension. All day phasing 
showed the right IOP to range from 21 to 24 mmHg, with the highest measurement recorded at 
9:30, and the left IOP from 22 to 25 mmHg, with highest reading at 13:00. After counselling the 
patient commenced treatment with Latanoprost 0.005% 1 drop at night to both eyes. Eight weeks 
later, the IOP was right 18 mmHg and left 17 mmHg. He was advised to carry on his topical 
medication and to come back in the Clinic in 6 months time for active monitoring. 
  
DISCUSSION 
The original description of a pigment spindle at the level of the endothelium dates back to 1899 in a 
manuscript by Krukenberg.1 Pigmentary glaucoma was first described as a rare entity by Sugar and 
Barbour in 1949.2 Prior to their manuscript both Levinsohn and Koeppe investigated the association 
between pigment release inside the eye and increased ocular hypertension or glaucoma.3,4 
Patients with PDS are more frequently young men with mild myopia and a posterior bowing iris 
profile. The rubbing between the posterior iris surface and the zonular apparatus, facilitated by a 
reverse papillary block mechanism, is the most accredited theory to account for the release and 
accumulation of iris pigment in these eyes.5,6 
 
In 1981 Mühlenweg and Naumann published a case report of a 59-year-old man with congenital 
cataracta pulverulenta centralis who had been kept on pharmacological mydriasis for 24 years with 
atropine 1%, scopolamine 0.25% or tyramine hydrochloride 2.5% every day or on alternate days to 
improve his vision.7 At the time of their observation the patient presented with signs typical of PDS; 
pigment keratic precipitates, highly pigmented trabecular meshwork, pigment deposits on the 
anterior iris surface and on the anterior hyaloid-capsular ligament (Egger’s line). They report bilateral 
increased intraocular pressure without clinical sign of glaucomatous optic neuropathy. Interestingly 
the patient described had iris transillumination defects next to the pupillary ruff instead of the mid-
iris periphery as more commonly observed in PDS patients. They interpreted that feature as the 
result of an excessive excursion of the pharmacologically dilated pupil on the anterior lenticular 
capsule causing the release of melanin pigment granules. They concluded that the patient had 
developed a rare form of secondary PDS, previously never described. To them the main difference 
from the primary form was the location of the iris chafing and therefore the position of the 
transillumination defects at the level of the pupillary margin, similarly to what can be sometimes 
found in pseudoexfolative syndrome and in senile pupillary atrophy. 
 
The patient we describe shares several signs with the patient reported by Mühlenweg and 
Naumann.7 Both cases had pigment dispersion syndrome with ocular hypertension and no evidence 
of glaucomatous optic neuropathy following many years of uninterrupted Atropine 1% instillation 
for congenital bilateral cataracts. Both cases presented with evidence of a Krukenberg spindle, 
increased diffuse trabecular meshwork pigmentation and iris transillumination defects. The main 
difference between our patient and the case reported by Mühlenweg and Naumann appears to be in 
the location of the iris transillumination defects. We observed them in the characteristic spoke 
pattern consistent with PDS; in contrast, Mühlenweg and Naumann noticed iris transillumination 
defects only around the pupillary ruff. 
 
The iris profile of our patient is concave, as shown in the SS AS-OCT 3D reconstruction (Fig. 1). 
Although this is a common trait of PDS patients, we feel this per se may not entirely explain the 
clinical picture. Our patient is a 45 year-old gentleman who has been on uninterrupted treatment 
with Atropine 1% ointment; hence he has been for most of his life in a permanent mid-dilated pupil 
state, unable to accommodate and with posteriorly displaced zonular ligaments. The long standing 
pharmacological cyclopegia is meant to keep the ciliary muscle in a relaxed state, therefore 
promoting a stretching of the zonular ligaments and a posterior movement of the zonulo-lenticular 
complex. All these conditions should have “protected” him from developing a PDS according to the 
most accredited pathogenetic theory (reverse pupillary block). 
 
It is relatively common to find myopic eyes with concave iris and yet without any of the hallmark 
signs of PDS. In an AS-OCT study investigating the iris configuration, Cheung et al8 highlighted that 
about 13% of the 46 healthy Chinese patients with open angle had a concave iris profile in an 
unaccommodated state. This configuration was maintained regardless of the room illumination 
(from bright to dim light), although the concavity was less pronounced in the darkness. This was 
probably due to a reduction in the posterior chamber volume and a concomitant increase in the 
posterior chamber pressure that led to a less concave profile. The subject with iris concavity were 
younger and had longer axial length compared to the others. 
 
Schuster et al9 reported that 26% of the 402 myopic eyes and 5% of the 93 emmetropic eyes 
investigated by means of Spectral Domain AS-OCT had a concave iris profile. Although they didn’t 
screen for PDS signs, it is unlikely that all the subjects with concave iris had PDS. They found that 
concave iris configuration was associated with young age, male gender and myopia. Shah et al10 
found in a cohort of 96 school boys that 24% exhibited an iris concave profile when analysed by 
means of Time Domain AS-OCT. Again, this percentage seems to exceed the previously reported 
prevalence of PDS in Caucasians of around 2.5%.11 Therefore iris concavity alone doesn’t appear to 
lead necessarily to PDS; on the contrary it may be that only a small proportion of the eyes with a 
posterior bowing iris progresses to PDS when in the presence of other predisposing factors. 
 
On the other hand, Liu et al12 showed with AS-OCT imaging on 33 eyes of 20 patients with PDS that 
the posterior bowing iris associated with PDS was reversed after fixation of a target, which led to a 
planar iris configuration. After accommodation the posterior bowing was restored. This suggests 
that the iris concavity associated with PDS might be associated with a different mechanism (reverse 
pupillary block triggered by accommodation and maintained by irido-lenticular contact) compared to 
that commonly found in healthy young myopic people. 
 
We speculate the long term usage of Atropine 1% may have contributed to the development of PDS 
in our patient. It is well known that mydriatic agents, such as cyclopentolate and phenylephrine, can 
cause pigment showers inside the eye, presumably due to a disruption of the pigmented cells of the 
posterior iris by the contraction of the dilator pupillae.13,14 It is also been shown that atropine binds 
to melanin in the iris15 and is a competitive antagonist for the cholinergic muscarinic M1-M5 
receptors in cutaneous melanocytes.16 These properties might cause, after prolonged exposure to 
the drug, two consequences: a greater susceptibility of the iris pigment epithelium (IPE) to physical 
and chemical damage and, provided that iris melanocytes share similar features with skin 
melanocytes, changes in the pattern and the amount of pigment distribution in the iris. 
 
Some papers have previously described the presence of an abnormal iris IPE and a hyperplastic iris 
dilator muscle in PDS eyes.17-19 The authors of those papers hypothesized that a congenital or 
developmental abnormality of the IPE was the main cause of PDS. The long term use of topical 
Atropine may have caused a similar predisposition in our patient, inducing changes at the level of 
the IPE and iris dilator. The IPE might become more fragile and susceptible to damage following 
chronic exposure to Atropine; at the same time the iris dilator might develop hyperplasia that makes 
the iris thicker and therefore closer to the zonular complex. The coincidental presence of a concave 
iris profile and a more anteriorly displaced zonular apparatus might have contributed as well to 
determine the onset of PDS in our patient. In the latter case, the condition could be regarded as part 
of an anterior segment dysgenesis case with a broader spectrum of alterations including congenital 
cataract and irido-zonular abnormalities. 
 
On the other hand a poor compliance to atropine 1% ointment may have also contributed to the 
development of a primary PDS. However it is unlikely that our patient discontinued the medication 
for a prolonged time since he had a beneficial impact on his vision from the use of the drug. The 
patient was reassessed in several different occasions and the pupil was always found to be mid 
dilated with no visible activity of the pupillary sphincter muscle. It is reasonable to think that the 
sphincter muscle developed a certain amount of atrophic changes following years of inactivity. Also 
it is unlikely that, on a once every 5-day regimen of Atropine 1%, the pupil returned to an undilated 
state before the following instillation. This because the effect of Atropine 1% lasts for up to 2 weeks 
and it is certainly still considerable at day 4 after instillation. 
These findings are of relevance for ophthalmologists considering long-term use of atropine to treat 
amblyopia or to reduce myopia progression. Even if these pigmentary changes occur in 1% or less of 
the patients, wide use of atropine in populations could produce a dramatic increase in pigmentary 
dispersion syndrome and potentially in pigmentary glaucoma. For example, in Taiwan around 50% of 
the myopic children receive atropine treatment to reduce myopia progression.20 Hence we would 
recommend clinicians and policy makers to be cautious until more evidence supports the safe use of 
a chronic treatment with topical atropine. 
 
To summarise, we describe a patient of a young male who developed PDS following many years of 
uninterrupted treatment with topical mydriatic agents to treat bilateral congenital cataracts. The 
mechanism responsible for that condition challenges the traditional theory on pigment dispersion 
syndrome development. 
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FIGURE 1. (Left-hand side, top and bottom): anterior segment photographs clearly showing spoke-
like midiris transillumination defects. (Right-hand side, top and bottom): anterior segment Swept-
Source OCT scans with 3D reconstruction effectively illustrate the posterior bowing of the iris profile. 
 
 
 
 
